Trial · NCT01235741
Results by group49
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 49
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change From Baseline to Week 1 and From Baseline to Month 6 Follow-up in Body Weight - Intent to Treat Population | Placebo | Week 1 | -0.34 | Standard Deviation 0.924 | percentage of change in weight |
| Percent Change From Baseline to Week 1 and From Baseline to Month 6 Follow-up in Body Weight - Intent to Treat Population | Pramlintide + Metreleptin | Week 1 | -0.26 | Standard Deviation 0.819 | percentage of change in weight |
| Percent Change From Baseline to Week 1 and From Baseline to Month 6 Follow-up in Body Weight - Intent to Treat Population | Placebo | 6 Month Follow-Up | -0.02 | Standard Deviation 6.575 | percentage of change in weight |
| Percent Change From Baseline to Week 1 and From Baseline to Month 6 Follow-up in Body Weight - Intent to Treat Population | Pramlintide + Metreleptin | 6 Month Follow-Up | -1.80 | Standard Deviation 6.063 | percentage of change in weight |
| Number of Participants With Treatment Emergent Adverse Events and Number With Post Treatment Adverse Events - Intent to Treat Population | On Treatment Placebo | 6 | participants | ||
| Number of Participants With Treatment Emergent Adverse Events and Number With Post Treatment Adverse Events - Intent to Treat Population | On Treatment Pramlintide + Metreleptin | 13 | participants | ||
| Number of Participants With Treatment Emergent Adverse Events and Number With Post Treatment Adverse Events - Intent to Treat Population | Post Treatment Placebo Arm | 13 | participants | ||
| Number of Participants With Treatment Emergent Adverse Events and Number With Post Treatment Adverse Events - Intent to Treat Population | Post Treatment Pramlintide + Metreleptin Arm | 16 | participants | ||
| Change From Baseline to Week 2, and to Follow up Months 2, 4, 6 in Fasting Leptin Concentration - Intent to Treat Population | Pramlintide + Metreleptin | Change from baseline to Week 2 of treatment | 223.38 | Standard Deviation 512.088 | ng/mL |
| Change From Baseline to Week 2, and to Follow up Months 2, 4, 6 in Fasting Leptin Concentration - Intent to Treat Population | Pramlintide + Metreleptin | Change from baseline to Month 2 Follow up | 15.46 | Standard Deviation 34.885 | ng/mL |
| Change From Baseline to Week 2, and to Follow up Months 2, 4, 6 in Fasting Leptin Concentration - Intent to Treat Population | Pramlintide + Metreleptin | Change from baseline to Month 4 Follow up | 20.08 | Standard Deviation 35.732 | ng/mL |
| Change From Baseline to Week 2, and to Follow up Months 2, 4, 6 in Fasting Leptin Concentration - Intent to Treat Population | Pramlintide + Metreleptin | Month 6 Follow up | 10.70 | Standard Deviation 18.913 | ng/mL |
| Number of Participants With Anti-leptin Antibodies Who Received Metreleptin - Intent to Treat Population | Pramlintide + Metreleptin | Week 1 | 0 | participants | |
| Number of Participants With Anti-leptin Antibodies Who Received Metreleptin - Intent to Treat Population | Pramlintide + Metreleptin | Week 2 | 1 | participants | |
| Number of Participants With Anti-leptin Antibodies Who Received Metreleptin - Intent to Treat Population | Pramlintide + Metreleptin | Early Termination | 9 | participants | |
| Number of Participants With Anti-leptin Antibodies Who Received Metreleptin - Intent to Treat Population | Pramlintide + Metreleptin | Month 2 Follow-Up | 15 | participants | |
| Number of Participants With Anti-leptin Antibodies Who Received Metreleptin - Intent to Treat Population | Pramlintide + Metreleptin | Month 4 Follow-Up | 10 | participants | |
| Number of Participants With Anti-leptin Antibodies Who Received Metreleptin - Intent to Treat Population | Pramlintide + Metreleptin | Month 6 Follow-Up | 8 | participants | |
| Number of Participants With Neutralizing Activity to Metreleptin at Early Termination or During Post Treatment Follow-Up - Intent to Treat Population Who Received Metreleptin | Pramlintide + Metreleptin | 0 | participants | ||
| Number of Participants With Hematology and Urinalysis Laboratory Values of Potential Clinical Importance - Intent to Treat Population | Placebo | Hematocrit | 0 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01235741/results